Chronic myeloid leukemia is a clonal disease that results from an acquired genetic change in a single pluripotential hemopoietic stem cell. Efforts to confront this disease have been assisted by advances in cellular and molecular biology and the speed at which these findings have transformed the therapeutic algorithm. Nevertheless, there is some uncertainty with regards to how best to assess efficacy of treatment, especially with regards to the most appropriate surrogate markers for overall survival. From the standpoint of biology and clinical management, this handbook provides an authoritative state-of-the-art review of current and developing progress.